Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.
about
Anti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infectionUropod elongation is a common final step in leukocyte extravasation through inflamed vessels.Extended interval dosing of natalizumab in multiple sclerosis.Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.Effects of natalizumab treatment on Foxp3+ T regulatory cells.Daclizumab treatment for multiple sclerosis.Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.The symptomatic management of multiple sclerosis.Have we overestimated the benefit of human(ized) antibodies?Natalizumab in the treatment of multiple sclerosisMacrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases.Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational studyMSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencingInfectious complications associated with monoclonal antibodies and related small moleculesImmunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNatalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Safety concerns and risk management of multiple sclerosis therapies.Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis.Early development of anti-natalizumab antibodies in MS patients.Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860
Q27322602-5F7E7CF7-B471-49F5-B6E0-136A91387F06Q30522340-562C624A-A80D-47C5-91B9-27DC1E49B1DAQ31049360-55AEEC3C-B1B0-4D3D-9F18-152EA0ED6253Q31108462-200535BC-A157-4629-AD29-2D62DB273D46Q33373995-FC32404F-52AB-4999-BCB2-17AEDBF9DA83Q33382919-49AE684C-BCA3-4117-9194-1DA49D0C8274Q33573208-49CAD8F4-8225-4BF0-9EAE-30A12701400AQ33670955-777297E5-D956-4EC4-A510-8EEC5E1F8E1EQ34142714-278D5875-A636-4B1B-AFF2-3EB661BE00C4Q34409340-233132E9-3A90-49C8-BF3C-A7A73CB23B01Q34785236-F3A3A041-CE86-4257-8CB6-351EBE01305EQ34994463-06D38073-49E4-48F5-9E5D-7A99B311B6ADQ36205344-ECAFC274-DC08-4DFC-B0C3-A3B00DF97760Q36433030-8E861727-31EA-476F-A41B-4F4F3C385BF6Q37156636-29E88444-CB57-44CA-8C6C-5E912EF01CC6Q37180592-98035834-CB46-48A6-BCB3-92089DAF5C19Q37213706-4D07FDCF-EFBF-4177-87E0-16C87C3862CFQ37696989-0DB4F70E-5A0F-47DF-8895-D9F3E4E788B2Q38256670-A20A38B9-D13D-4A47-A2C1-51F8AAFE5D1FQ38558344-481EEC7A-0400-4F12-92BE-0AD9C1EEB761Q38960854-94457AAD-54EB-4CD4-998A-B3CB115496C0Q39021781-11788C74-52E4-42A8-8EF0-6B4B4850D9CEQ41899890-384D96D4-3CDD-4F62-A6E2-4D9E9F8CA04DQ44572216-59A3450B-EF88-44CF-B349-52D79284EEC5Q46979111-6DD88D9A-4E3F-41A7-A214-8A3CDB8B04E5Q48370561-4BB5A475-8464-4EB4-9BFE-B79AD083B03CQ48629242-8F1DAC21-E424-4BFE-B90D-35F07B67D9C4Q51707094-1379E29F-01E3-4AF5-A430-FF18F7D295ADQ59129976-32A2BFFE-7A28-43BD-8DAA-202B2CFED3FA
P2860
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacological properties, to ...... bri) in inflammatory diseases.
@ast
Pharmacological properties, to ...... bri) in inflammatory diseases.
@en
type
label
Pharmacological properties, to ...... bri) in inflammatory diseases.
@ast
Pharmacological properties, to ...... bri) in inflammatory diseases.
@en
prefLabel
Pharmacological properties, to ...... bri) in inflammatory diseases.
@ast
Pharmacological properties, to ...... bri) in inflammatory diseases.
@en
P2860
P1476
Pharmacological properties, to ...... bri) in inflammatory diseases.
@en
P2093
Jeffrey L Bennett
Olaf Stüve
P2860
P356
10.1111/J.1527-3458.2007.00003.X
P50
P577
2007-01-01T00:00:00Z